Aardal Eriksson Elisabeth, Mobäck Caroline, Jakobsson Sandra, Hoffmann Johannes J M L
Department of Clinical Chemistry, University Hospital, Linköping, Sweden.
Abbott Diagnostics, Department of Medical & Scientific Affairs, Abbott GmbH & Co. KG, Wiesbaden, Germany.
Transfus Apher Sci. 2015 Aug;53(1):76-81. doi: 10.1016/j.transci.2015.03.011. Epub 2015 Mar 18.
Blood donation is associated with iron depletion, but donor iron status is not usually investigated, as such tests are cumbersome and costly. It would therefore be desirable to have simple, fast and inexpensive tests that give information on a donor's risk of developing iron depletion. In a pilot study we investigated whether novel erythrocyte and reticulocyte parameters can serve this goal.
In regular blood donors extended red cell parameters were measured using the Abbott CELL-DYN Sapphire hematology analyzer and conventional biochemical tests of iron status. Donors were compared with a regionally matched group of non-donating controls.
In the controls, the reference ranges of extended RBC parameters were well comparable to published data. Donors had significantly more microcytic RBC than controls (median 0.9 vs 0.6%), lower serum ferritin concentration (median 43 vs 91 mg/L) and higher soluble transferrin receptor/ferritin index (median 1.60 vs 1.27). Overall 18-28% of the donors were iron depleted. Moreover, 3.3% of donors had iron-restricted erythropoiesis. Microcytic RBC and reticulocyte mean cell hemoglobin content predicted iron depletion with 70% and 64% sensitivities and specificities of 72% and 78%, respectively. When combined these two parameters increased the sensitivity to 82%.
Our results in Swedish blood donors confirm a high prevalence of iron depletion, despite iron supplementation used by about half of the donors. Microcytic RBC and MCHr appeared to be helpful in identifying iron-depleted donors, who might benefit from iron supplementation. We recommend larger prospective investigations in order to confirm and extend the findings of this pilot study.
献血与铁缺乏有关,但通常不会对献血者的铁状态进行调查,因为此类检测既繁琐又昂贵。因此,需要有简单、快速且廉价的检测方法来提供献血者发生铁缺乏风险的信息。在一项初步研究中,我们调查了新型红细胞和网织红细胞参数是否能实现这一目标。
使用雅培CELL-DYN Sapphire血液分析仪对定期献血者进行扩展红细胞参数测量,并进行铁状态的常规生化检测。将献血者与区域匹配的非献血对照组进行比较。
在对照组中,扩展红细胞参数的参考范围与已发表数据具有良好的可比性。献血者的小细胞红细胞明显多于对照组(中位数0.9%对0.6%),血清铁蛋白浓度较低(中位数43对91mg/L),可溶性转铁蛋白受体/铁蛋白指数较高(中位数1.60对1.27)。总体而言,18%-28%的献血者存在铁缺乏。此外,3.3%的献血者存在铁限制红细胞生成。小细胞红细胞和网织红细胞平均细胞血红蛋白含量预测铁缺乏的敏感性分别为70%和64%,特异性分别为72%和78%。将这两个参数结合使用时,敏感性提高到82%。
我们在瑞典献血者中的研究结果证实,尽管约一半的献血者使用了铁补充剂,但铁缺乏的患病率仍然很高。小细胞红细胞和网织红细胞平均细胞血红蛋白含量似乎有助于识别可能从铁补充剂中受益的铁缺乏献血者。我们建议进行更大规模的前瞻性研究,以证实和扩展这项初步研究的结果。